Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × donafenib × Clear all
NCT02698111 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡